cilostazol has been researched along with Diabetic Angiopathies in 16 studies
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 9.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| " Cilostazol and pentoxifylline are the only two drugs that have been approved for the treatment of patients with intermittent claudication." | 9.09 | Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. ( Lee, TM; Lee, YT; Su, SF; Tsai, CH; Wang, SS, 2001) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 6.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 5.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| " Cilostazol and pentoxifylline are the only two drugs that have been approved for the treatment of patients with intermittent claudication." | 5.09 | Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. ( Lee, TM; Lee, YT; Su, SF; Tsai, CH; Wang, SS, 2001) |
| "Patients on cilostazol were divided into 4 groups according to arterial occlusive disease etiology: (1) atherosclerosis, (2) diabetic angiopathy, (3) embolism/thrombosis, and (4) Buerger disease." | 4.31 | Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol? ( Arslan, K; Can Depboylu, B; Funda Tetik, M; Harmandar, B; Ilhan, G; Istar, H; Yazman, S, 2023) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 2.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| " The measurement of digital skin temperatures by infrared thermography provided a noninvasive means to individualize the dosage of cilostazol and to monitor the cilostazol effect and patient complicance during long-term administration." | 2.67 | Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. ( Furukawa, H; Murakami, T; Uchikawa, T, 1992) |
| "Cilostazol has potential for protecting vessels against hyperglycemic injury and for accelerating the healing process after implantation of DES." | 1.39 | Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model. ( Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Can Depboylu, B | 1 |
| Yazman, S | 1 |
| Harmandar, B | 1 |
| Funda Tetik, M | 1 |
| Istar, H | 1 |
| Arslan, K | 1 |
| Ilhan, G | 1 |
| Su, SC | 1 |
| Hung, YJ | 1 |
| Huang, CL | 1 |
| Shieh, YS | 1 |
| Chien, CY | 1 |
| Chiang, CF | 1 |
| Liu, JS | 1 |
| Lu, CH | 1 |
| Hsieh, CH | 1 |
| Lin, CM | 1 |
| Lee, CH | 1 |
| Kwon, JS | 1 |
| Kim, YS | 3 |
| Cho, HH | 1 |
| Kee, HJ | 1 |
| Hong, MH | 1 |
| Kang, WS | 1 |
| Jeong, HY | 1 |
| Jeong, MH | 1 |
| Ahn, Y | 1 |
| Asal, NJ | 1 |
| Wojciak, KA | 1 |
| Angiolillo, DJ | 2 |
| Capranzano, P | 2 |
| Goto, S | 1 |
| Aslam, M | 1 |
| Desai, B | 2 |
| Charlton, RK | 1 |
| Suzuki, Y | 1 |
| Box, LC | 1 |
| Shoemaker, SB | 1 |
| Zenni, MM | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Rhee, SY | 1 |
| Chon, S | 1 |
| Oh, S | 1 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Kim, JW | 1 |
| Fu, Q | 1 |
| Yokoyama, N | 1 |
| Takada, K | 1 |
| Ishikawa, S | 1 |
| Isshiki, T | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Capodanno, D | 1 |
| Dharmashankar, K | 1 |
| Darlington, A | 1 |
| Tello-Montoliu, A | 1 |
| Rollini, F | 1 |
| Hittel, N | 1 |
| Donnelly, R | 1 |
| Lee, SW | 1 |
| Park, SW | 2 |
| Kim, YH | 1 |
| Yun, SC | 1 |
| Park, DW | 1 |
| Lee, CW | 1 |
| Hong, MK | 1 |
| Kim, HS | 1 |
| Ko, JK | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Choi, SW | 1 |
| Seong, IW | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Kim, JH | 1 |
| Chun, KJ | 1 |
| Park, SJ | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Falconer, TM | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 1 |
| Norman, PE | 1 |
| Ahn, CW | 1 |
| Lee, HC | 1 |
| Song, YD | 1 |
| Huh, KB | 1 |
| Oh, SJ | 1 |
| Choi, YK | 1 |
| Kim, JM | 1 |
| Lee, TH | 1 |
| Lee, TM | 1 |
| Su, SF | 1 |
| Tsai, CH | 1 |
| Lee, YT | 1 |
| Wang, SS | 1 |
| Shinoda-Tagawa, T | 1 |
| Yamasaki, Y | 1 |
| Yoshida, S | 1 |
| Kajimoto, Y | 1 |
| Tsujino, T | 1 |
| Hakui, N | 1 |
| Matsumoto, M | 1 |
| Hori, M | 1 |
| Uchikawa, T | 1 |
| Murakami, T | 1 |
| Furukawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for cilostazol and Diabetic Angiopathies
| Article | Year |
|---|---|
Effect of cilostazol in treating diabetes-associated microvascular complications.
Topics: Cilostazol; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; Tetrazoles | 2017 |
Treating peripheral arterial disease in patients with diabetes.
Topics: Cilostazol; Diabetic Angiopathies; Disease Progression; Humans; Peripheral Vascular Diseases; Phosph | 2002 |
Management of peripheral arterial disease in the elderly: focus on cilostazol.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hy | 2008 |
7 trials available for cilostazol and Diabetic Angiopathies
| Article | Year |
|---|---|
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove | 2008 |
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies | 2013 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Blood Pressure; Carotid Artery, Common; Cilostazol; Coronary Disease; Diabetes Mellit | 2001 |
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Double-Blind Method; Endothelial Growth Factors; Exercise T | 2001 |
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.
Topics: Aged; Asian People; Carotid Arteries; Cerebral Infarction; Cilostazol; Diabetes Mellitus, Type 2; Di | 2002 |
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis Obliterans; Cilostazol; Diabetic Angiopathies; Female; Fingers; Humans | 1992 |
6 other studies available for cilostazol and Diabetic Angiopathies
| Article | Year |
|---|---|
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
Topics: Atherosclerosis; Cilostazol; Diabetic Angiopathies; Humans; Peripheral Arterial Disease; Quality of | 2023 |
Cilostazol inhibits hyperglucose-induced vascular smooth muscle cell dysfunction by modulating the RAGE/ERK/NF-κB signaling pathways.
Topics: Animals; Cilostazol; Diabetic Angiopathies; Glucose; Male; MAP Kinase Signaling System; Mice; Mice, | 2019 |
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucos | 2013 |
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty | 2011 |
Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Cilostazol; Clopidogr | 2010 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |